# Anchor Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anchor-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.anchortx.com
- Total disclosed funding: $38M
- Latest round: Series B (Aug 20, 2010)
- Investors on record: 3

## About

Anchor Therapeutics specializes in the sale of premium domain names, catering to businesses and entrepreneurs aiming for a distinctive online presence. Their offerings ensure a secure purchasing process backed by a satisfaction guarantee.Anchor Therapeutics, founded in 2006 and headquartered in Cambridge, US, focuses on providing high-value domain names. The company has completed a total of 3 deals, with its most recent funding round occurring on August 20, 2010. During this Series B round, Anchor Therapeutics raised USD 10.00 mn from investors including HealthCare Ventures, Novartis Venture Fund, and TVM Capital Life Science. The current company valuation stands at USD 32.06 mn.Anchor Therapeutics offers premium domain names for sale, including the notable AnchorTX.com, which is listed at a price of USD 7,695. Clients can choose to purchase outright or opt for a payment plan of USD 320.63 per month over 24 months. The company provides secure transactions through payment methods like PayPal and Escrow.com, targeting a diverse customer base across technology, finance, and e-commerce sectors primarily in North America and Europe.Anchor Therapeutics generates revenue through the direct sale of domain names, allowing clients flexible purchasing options. The domain name AnchorTX.com is available for USD 7,695 or a payment plan of USD 320.63 monthly for 24 months. This dual approach caters to various buyers, from startups to established enterprises, through secure transaction methods.Anchor Therapeutics plans to leverage its recent Series B funding of USD 10.00 mn to enhance its product offerings and expand its market presence. This includes upcoming initiatives aimed at enhancing their domain acquisition process and targeting additional regions in North America and Europe. The funding is expected to support these strategic expansions and product developments as they look to broaden their client base and improve their services.

## Funding rounds

- Series B, Aug 20, 2010, $10M — HealthCare Ventures, TVM Capital Life Science, Novartis Venture Fund
- Series A, Nov 18, 2008, $19M — HealthCare Ventures, TVM Capital Life Science, Novartis Venture Fund
- Series A, Oct 16, 2007, $9M — HealthCare Ventures, TVM Capital Life Science, Novartis Venture Fund

## Investors

- HealthCare Ventures — Series A, Series B
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B